Questions raised by the Benelux CML study group: Results from the randomized study with hydroxyurea alone versus hydroxyurea combined with low- dose interferon-α 2b for chronic myeloid leukemia [10] (multiple letters)

Blood

Volumn 92, Issue 8, 1998, Pages 2984-2987

  Kantarjian, H M ^a   Talpaz, M ^a   Kluin Nelemans, J C ^a   Delannoy, A ^a   Louwagie, A ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ALPHA2B INTERFERON; ANTILEUKEMIC AGENT; CYTARABINE; HOMOHARRINGTONINE; HYDROXYUREA;

BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CHRONIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CYTOGENETICS; DRUG INDUCED DISEASE; HUMAN; LETTER; MAJOR CLINICAL STUDY; META ANALYSIS; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0032532636     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v92.8.2984     Document Type: Letter

References (0)